Frontlight ResearchEarly access
CompletedPhase 2
SHR-2004 for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty
Key facts
- Who runs it
- Beijing Suncadia Pharmaceuticals Co., Ltd
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 353 people enrolled
- Started
- 12 Apr 2023
- Ended
- 25 Jun 2024
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- SHR-2004 injection
- Enoxaparin sodium injection
- Record updated
- 20 January 2025
Who can take part
- Age
- 40 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Understand the research procedures and methods, volunteer to participate in the study, and sign the informed consent
- Scheduled to undergo elective unilateral total knee arthroplayts (TKA)
- Male or female(≥ 40 years old and < 80 years old)
Who cannot take part
- Malignant tumor within one year of the screening
- History of venous thromboembolism
- Myocardial infarction, transient ischemic attack or ischemic stroke occurred within 6 months of the screening
- Any medical history that may increase the risk of bleeding or any conditions that the investigator considers to increase the risk of bleeding
- History of drug abuse
- Any of the laboratory test indicators meets the following criteria:; ①estimated Glomerular Filtration Rate < 60 mL/min/1.73m2 ; ②Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 times the upper limit of normal value (ULN); ③total bilirubin was > 2 times, etc
- Unable to receive CT angiography of both lower limbs
- Pregnant or lactating women
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of the study is to evaluate the efficacy and safety of SHR-2004 in preventing venous thromboembolism after elective unilateral total knee arthroplasty
The 4 groups in the trial
- Treatment group A: SHR-2004 injectionTreatment being tested
Treatment: SHR-2004 injection
- Treatment group B: SHR-2004 injectionTreatment being tested
Treatment: SHR-2004 injection
- Treatment group C: SHR-2004 injectionTreatment being tested
Treatment: SHR-2004 injection
- Treatment group D: Enoxaparin sodium injectionExisting treatment, for comparison
Treatment: Enoxaparin sodium injection
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Randomized, Active-comparator-controlled Phase 2 Clinical Trial to Assess the Efficacy and Safety of a Single Subcutaneous Injection of SHR-2004 in Patients Undergoing Elective Unilateral Total Knee Arthroplasty
- Record updated
- 20 January 2025